Early Lapatinib-Induced Skin Rash Predicts Better Survival With

Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.

HER2-positive breast cancer and tyrosine kinase inhibitors: the

Lapatinib with trastuzumab for HER2-positive early breast cancer

Number of days from start of lapatinib to onset of rash

Lapatinib: Package Insert

Update on systemic treatment for newly diagnosed inflammatory

Molecular Heterogeneity and Response to Neoadjuvant Human

PDF] Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO

Forest plots showing heterogeneity by rash phenotype in the TþL

Lapatinib (Tyverb)

Efficacy of lapatinib monotherapy on occult breast cancer

Frontiers Exceptional and Durable Responses to TDM-1 After

Effects of lapatinib monotherapy: results of a randomised phase II

Targeting HER2-positive breast cancer: advances and future